Why Ascentage Pharma Group International’s (AAPG) Stock Is Down 6.70%
As of Monday, November 16, Ascentage Pharma Group International’s AAPG share price has dipped by 6.70%, which has investors questioning if this is right time to buy.Tudor Pop
| SECTOR | INDUSTRY |
| Health Care | Biotechnology |
A+ Stock Grade Summary:
| VALUE: |
|
|
| GROWTH: |
|
|
| MOMENTUM: |
|
|
| EPS REVISIONS: |
|
|
| QUALITY: |
|
|
Tudor Pop
Jenna Brashear
Tudor Pop
Rosalio Madrigal
Jenna Brashear
| Share Statistics | AAPG | Industry Median |
Percentile (All Stocks) |
|
| Market Cap (Mil) | $1,317.0 | $211.8 | 49% |
|
| Shares Out (Mil) | 54.9 | 55.4 | 49% |
|
| Institutional Ownership | 56.4% | 93.0% | 38% |
|
| Float (Mil) | 284.4 | 41.5 | 79% |
|
| Beta | 0.67 | 0.99 | 38% |
|
| Avg Daily Volume (000s) | 7 | 553 | 16% |
|
| Price Change (52-week) |
(56.3%) | 42.8% | 17% |
|
| Growth | AAPG | Industry Median |
Percentile (All Stocks) |
|
| Sales (5yr) | 112.4% | 13.2% | 99% |
|
| Net Income (5yr) | (11.4%) | (10.3%) | 28% |
|
| EPS (5yr) | (0.7%) | 15.8% | 30 |
|
| Dividends (5yr) | 0.0% | 0.0% | 0% |
|
| Cash Flow (5yr) | (8.1%) | (15.7%) | 59% |
|
| Estimates | Qtrly | Current Fiscal Year |
Next Fiscal Year |
|
| # of Estimates | na | na | na | |
| Current EPS | na | na | na | |
| Month Ago EPS | na | na | na | |
| # Rev Up | na | na | na | |
| # Rev Down | na | na | na | |
| Three Months Ago EPS | na | na | na | |
| Year/Year Chg | na | na | na | |
| Financials | AAPG | Industry Median |
Percentile (All Stocks) |
|
| Sales (TTM) (Mil) | $95 | $41 | 25% |
|
| Net Income (TTM) (Mil) | ($216) | ($44) | 6% |
|
| EPS (TTM) | ($0.581) | ($1.500) | 25% |
|
| Operating Cash Flow (TTM) (Mil) | ($195) | ($35) | 4% |
|
| Net Cash Flow (TTM) (Mil) | $124 | $-0 | 80% |
|
| Long-Term Debt (Q1) (Mil) | $91 | $4 | 43% |
|
| Enterprise Value (Q1) (Mil) | $1,561 | $147 | 46% |
|
| Valuation | AAPG | Industry Median |
Percentile (All Stocks) |
|
| P/B | 66.45 | 2.01 | 99% |
|
| P/E | na | 17.9 | na |
|
| Dividend Yield | 0.0% | 0.0% | 0% |
|
| PEG (5yr hist) | na | 1.0 | na |
|
| Ratios | AAPG | Industry Median |
Percentile (All Stocks) |
|
| Gross Margin | 93.9% | 67.9% | 95% |
|
| Net Margin | (228.5%) | (50.6%) | 4% |
|
| ROA | (47.9%) | (47.4%) | 12% |
|
| ROE | (247.3%) | (53.1%) | 3% |
|
| Liabilities to Assets | 82.5% | 29.7% | 77% |
|
| F-Score | 4 | 3 | 34% |
|
Ascentage Pharma Group International did not pass any screens on 11/13/2026.
Price and market data provided by QuoteMedia and delayed a minimum of 15 minutes unless otherwise indicated. Fundamental data provided by AAII's Stock Investor Pro and S&P Global Market Intelligence and are updated through the previous trading day.
Ⓒ 2026 American Association of Individual Investors